FOIA release exposes a redacted revenue-share clause in Pfizer’s 2025 drug pricing deal with HHS

A watchdog group, not the company, put this term into the public record. Public Citizen obtained Pfizer's most favored nation contract with the U.S. Department of Health and Human Services through a FOIA lawsuit and released it on September 19, revealing a clause under which HHS receives a share of any additional revenue PFE generates by raising drug prices in overseas markets. Pfizer signed the underlying deal on September 30, 2025 and did not disclose the revenue-share mechanism at the time.

The specific share percentage is redacted in the released documents, and no source establishes whether it is capped. What is visible is the term: the agreement runs from January 1, 2026 through January 20, 2029. Eli Lilly signed a comparable agreement roughly two months after Pfizer's, and its contract was released in the same batch.

The structure inverts the usual read on international pricing. Under a most favored nation framework the pressure is on companies to lower U.S. prices toward what other countries pay, and this clause gives the government a direct financial interest in Pfizer raising prices abroad instead. That aligns the two parties on overseas pricing in a way that was not apparent from the 2025 announcement.

More than two dozen manufacturer agreements are understood to exist under this framework, but only the Pfizer and Lilly contracts have been made public, so whether the others carry the same clause is unknown rather than confirmed.

There is no market reaction to report. The documents were released on a Saturday and no trading session has occurred since. PFE closed at $27.66 on Friday, September 18, before the release, so that print says nothing about how investors read this. The next session is the first opportunity to see it priced.